Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial

Cytotherapy

Volumn 12, Issue 6, 2010, Pages 721-734

  Trepiakas, Redas ^a,b   Berntsen, Annika ^a,b   Hadrup, Sine Reker ^a   Bjørn, Jon ^a   Geertsen, Poul F ^b   Straten, Per Thor ^a   Andersen, Mads H ^a   Pedersen, Anders E ^c   Soleimani, Amir ^c   Lorentzen, Torben ^a   Johansen, Julia S ^a   Svane, Inge Marie ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer vaccination; Dendritic cells; Malignant melanoma; Regulatory T cells

Indexed keywords

ALPHA2B INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6; PROTEIN P53; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; SURVIVIN; TELOMERASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG PULSE THERAPY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; VACCINATION;

EID: 77957319524     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653241003774045     Document Type: Article

References (69)

1. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002;16:4-10.
2. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol. 2002;3:89-96.
3. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor SP, Svane IM. Review of clinical studies on dendritic cellbased vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1-14.
4. Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DN. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 1999;93:728-36.
5. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-51.
6. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-35.
7. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-42.
8. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Fidolfi L, Ballordini M, et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med. 2006;4:36.
9. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13:905-18.
10. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in fi rstline treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-70.
11. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008;26:2824-32.
12. Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood. 2000;96:3499-504.
13. Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas MA, Caron D, et al. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002;72:546-53.
14. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
15. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21:674-9.
16. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869-72.
17. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, Thor SP. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964-8.
18. + T lymphocytes. Clin Cancer Res. 2004;10:828-39.
19. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA. 2002;99:12275-80.
20. Otto K, Andersen MH, Eggert A, Firat H, Schmidt JD, Langlade-Demoyen P, et al. Lack of toxicity of therapyinduced T cell responses against the universal tumour antigen survivin. Vaccine. 2005;23:884-9.
21. Sievers E, Albers P, Schmidt-Wolf IG, Marten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol. 2004;171:114-9.
22. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase I/II trial. J Immunother. 2008;31:771-80.
23. Barfoed AM, Petersen TR, Kirkin AF, Thor SP, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000;51:128-33.
24. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci. 2000;910:121-37.
25. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994;4:35-45.
26. + T cells specific for the wild-type sequence p53 (264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 2002;62:3521-9.
27. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol. 1995;25:1765-9.
28. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004;53:633-41.
29. Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 2007;56(9):1485-99.
30. Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 2004;18:235-43.
31. Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol. 2005;61:147-56.
32. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61:2618-24.
33. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigenpresenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65:5417-27.
34. Maecker B, Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005;141:558-62.
35. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-33.
36. *0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother. 2007;56:1755-63.
37. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001;7:3343-8.
38. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002;62:2600-5.
39. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, et al. Human telomerase reverse transcriptasespecific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003;9:4743-55.
40. + T cells in colorectal cancer patients. Cancer Res. 2003;63:4507-15.
41. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, Straten Pt, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004;3:173-9.
42. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004;108:937-41.
43. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res. 1998;18:79-92.
44. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535-44.
45. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24:1958-65.
46. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
47. Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009;70:481-9.
48. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med. 2006;12:246-51.
49. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc. 2006;1:1120-32.
50. +T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res. 2004;10:4754-60.
51. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, et al. Chondrex: new marker of joint disease. Clin Chem. 1998;44:509-16.
52. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172-209.
53. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2007;1-20.
54. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van VJ, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6:520-6.
55. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol. 2006;50:34-43.
56. + and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-807.
57. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2005;1-5.
58. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878-87.
59. + memory T cells. Cancer Res. 2003;63:5582-6.
60. Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol. 2008;423:139-53.
61. Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schuler G, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods. 2003;277:1-16.
62. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55:819-29.
63. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-7.
64. + regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose IL-2. J Immunotherapy In press.
65. Svane IM, Pedersen AE, Nikolajsen K, Zocca MB. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine. 2008;26:4716-24.
66. van Dervliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13:2100-8.
67. + regulatory T cells in cancer patients. Blood. 2006;107:2409-14.
68. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8.
69. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer. 2008;124:130-9.